Ardelyx, Inc. 41X.F Stock
Ardelyx, Inc. Price Chart
Ardelyx, Inc. 41X.F Financial and Trading Overview
| Ardelyx, Inc. stock price | 7.13 EUR |
| Previous Close | 4.7 EUR |
| Open | 4.77 EUR |
| Bid | 4.92 EUR x 100000 |
| Ask | 4.96 EUR x 100000 |
| Day's Range | 4.77 - 4.77 EUR |
| 52 Week Range | 1.66 - 4.86 EUR |
| Volume | 1K EUR |
| Avg. Volume | 941 EUR |
| Market Cap | 1.13B EUR |
| Beta (5Y Monthly) | 1.042 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.26 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.21 EUR |
41X.F Valuation Measures
| Enterprise Value | 960.4M EUR |
| Trailing P/E | N/A |
| Forward P/E | -4.042373 |
| PEG Ratio (5 yr expected) | -0.03 |
| Price/Sales (ttm) | 8.443266 |
| Price/Book (mrq) | 5.795869 |
| Enterprise Value/Revenue | 7.153 |
| Enterprise Value/EBITDA | -60.441 |
Trading Information
Ardelyx, Inc. Stock Price History
| Beta (5Y Monthly) | 1.042 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 4.86 EUR |
| 52 Week Low | 1.66 EUR |
| 50-Day Moving Average | 3.8 EUR |
| 200-Day Moving Average | 3.67 EUR |
41X.F Share Statistics
| Avg. Volume (3 month) | 941 EUR |
| Avg. Daily Volume (10-Days) | 209 EUR |
| Shares Outstanding | 232.14M |
| Float | 227.07M |
| Short Ratio | N/A |
| % Held by Insiders | 1.52% |
| % Held by Institutions | 54.83% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -19.78% |
| Operating Margin (ttm) | 13.11% |
| Gross Margin | 64.00% |
| EBITDA Margin | -11.83% |
Management Effectiveness
| Return on Assets (ttm) | -4.88% |
| Return on Equity (ttm) | -20.59% |
Income Statement
| Revenue (ttm) | 134.27M EUR |
| Revenue Per Share (ttm) | 0.64 EUR |
| Quarterly Revenue Growth (yoy) | 1031.00% |
| Gross Profit (ttm) | 15.54M EUR |
| EBITDA | -15890000 EUR |
| Net Income Avi to Common (ttm) | -26570000 EUR |
| Diluted EPS (ttm) | -0.06 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 165.08M EUR |
| Total Cash Per Share (mrq) | 0.71 EUR |
| Total Debt (mrq) | 34.44M EUR |
| Total Debt/Equity (mrq) | 18.02 EUR |
| Current Ratio (mrq) | 5.542 |
| Book Value Per Share (mrq) | 0.823 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -66715000 EUR |
| Levered Free Cash Flow (ttm) | -32490376 EUR |
Profile of Ardelyx, Inc.
| Country | Germany |
| State | MA |
| City | Waltham |
| Address | 400 Fifth Avenue |
| ZIP | 02451 |
| Phone | 510 745 1700 |
| Website | https://www.ardelyx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 133 |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Q&A For Ardelyx, Inc. Stock
What is a current 41X.F stock price?
Ardelyx, Inc. 41X.F stock price today per share is 7.13 EUR.
How to purchase Ardelyx, Inc. stock?
You can buy 41X.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ardelyx, Inc.?
The stock symbol or ticker of Ardelyx, Inc. is 41X.F.
Which industry does the Ardelyx, Inc. company belong to?
The Ardelyx, Inc. industry is Biotechnology.
How many shares does Ardelyx, Inc. have in circulation?
The max supply of Ardelyx, Inc. shares is 235.24M.
What is Ardelyx, Inc. Price to Earnings Ratio (PE Ratio)?
Ardelyx, Inc. PE Ratio is now.
What was Ardelyx, Inc. earnings per share over the trailing 12 months (TTM)?
Ardelyx, Inc. EPS is -0.26 EUR over the trailing 12 months.
Which sector does the Ardelyx, Inc. company belong to?
The Ardelyx, Inc. sector is Healthcare.